These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 11862588

  • 1. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, Scudamore CH, Cuervas-Mons V, Metselaar HJ, Prestele H, Girault D.
    Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
    [Abstract] [Full Text] [Related]

  • 2. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
    Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff L, Hall M, Korn A, Nashan B, CHIC 304 International Liver Study Group.
    Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
    [Abstract] [Full Text] [Related]

  • 3. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 4. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP.
    Lancet; 1997 Oct 25; 350(9086):1193-8. PubMed ID: 9652559
    [Abstract] [Full Text] [Related]

  • 5. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
    Gruttadauria S, Vasta F, Mandalà L, Cintorino D, Piazza T, Spada M, Verzaro R, Gridelli B.
    Transplant Proc; 2005 Oct 25; 37(6):2611-3. PubMed ID: 16182762
    [Abstract] [Full Text] [Related]

  • 6. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.
    Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, Crocker JF, Cochat P, Clark G, Chodoff L, Korn A, Hall M.
    Transplantation; 2002 Oct 15; 74(7):961-6. PubMed ID: 12394837
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M, Kahn D, Kashi H, Salmela K, Fricke L, Heemann U, Garcia-Martinez J, Lechler R, Prestele H, Girault D, Simulect Phase IV Study Group.
    Transplantation; 2001 Oct 15; 72(7):1261-7. PubMed ID: 11602853
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 10. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D, Simulect International Study Group.
    Transplantation; 2003 Jan 15; 75(1):37-43. PubMed ID: 12544868
    [Abstract] [Full Text] [Related]

  • 11. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine.
    Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, Risaliti A, Burra P, Agnes S, De Carlis L, Valente U, Ferrara R, Pisati R.
    Transplantation; 2004 Nov 27; 78(10):1488-95. PubMed ID: 15599313
    [Abstract] [Full Text] [Related]

  • 12. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE.
    Transplantation; 2000 Feb 27; 69(4):488-96. PubMed ID: 10708100
    [Abstract] [Full Text] [Related]

  • 13. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM, Keating GM.
    Drugs; 2003 Feb 27; 63(24):2803-35. PubMed ID: 14664658
    [Abstract] [Full Text] [Related]

  • 14. Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation: comparative study.
    Gibelli NE, Pinho-Apezzato ML, Miyatani HT, Maksoud-Filho JG, Silva MM, Ayoub AA, Santos MM, Velhote MC, Tannuri U, Maksoud JG.
    Transplant Proc; 2004 May 27; 36(4):956-7. PubMed ID: 15194332
    [Abstract] [Full Text] [Related]

  • 15. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K, Arnol M, Bren AF, Kmetec A, Tomaziĉ J, Kandus A.
    Transplant Proc; 2007 Dec 27; 39(10):3093-7. PubMed ID: 18089329
    [Abstract] [Full Text] [Related]

  • 16. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM, Oh CK, Jin SH, Kim JH, Kim SJ, Kim H, Shin GT.
    Transplant Proc; 2006 Sep 27; 38(7):2025-8. PubMed ID: 16979988
    [Abstract] [Full Text] [Related]

  • 17. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD, Rajagopalan PR, Hall M.
    Transplantation; 1999 Jan 27; 67(2):276-84. PubMed ID: 10075594
    [Abstract] [Full Text] [Related]

  • 18. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    J Surg Res; 2007 Apr 27; 138(2):198-204. PubMed ID: 17292404
    [Abstract] [Full Text] [Related]

  • 19. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience.
    Kandus A, Grego K, Arnol M, Kovac D, Lindic J, Buturović J, Ponikvar R, Bren AF.
    Transplant Proc; 2006 Nov 27; 38(9):2853-5. PubMed ID: 17112847
    [Abstract] [Full Text] [Related]

  • 20. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    Transplant Proc; 2006 Dec 27; 38(10):3633-5. PubMed ID: 17175352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.